Figure 2.

Net risk of ipsilateral invasive breast cancer (iIBC) in patients without locoregional treatment, based on US National Cancer Institute’s Surveillance, Epidemiology, and End Results program (SEER) (1992–2014). The cumulative net risk of iIBC in the SEER no-treatment cohort is shown for all cases combined (A) and stratified by tumor grade (B), estrogen receptor (ER) status (C), tumor size (D), and age at diagnosis (E). The net risk (up to 10 years only) of iIBC in “low-risk” patients (40 years or older at diagnosis, nonhigh-grade, and ER and/or progesterone receptor-positive ductal carcinoma in situ) is shown in (F). The number of patients at risk is shown beneath the figures. Subgroup comparisons (excluding unknowns) were performed using a log-rank test.